ArticleJournal of molecular medicine (Berlin, Germany)2024

PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.

Manjiao Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.